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ABSTRACT 
 
Pulsatile drug delivery systems have been a major field of research recently. It is the most interesting time-specific 
and site-specific system. This system is designed for chronopharmacotherapy which is based on circadian rhythm. 
This means these systems will deliver drug at the time when disease displays it's most morbid and mortal state 
within a circadian cycle. The use of these systems has been investigated on diseases like asthma, arthritis, ulcers, 
cardiovascular diseases, hypercholesterolemia, cancer etc. Various capsular, osmotic, single and multiple unit 
systems that are modulated by soluble or erodible polymer coatings, rupturable membranes are discussed in the 
article below. 
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Introduction  
Concept of chronopharmaceutics also referred as 
chronopharmacotherapy has been emerged nowadays. 
It consists of two words chronobiology and 
pharmaceutics. Chronobiology is the science of 
biological rhythms and its mechanism [1]. Research is 
devoted to the design and evaluation of 
chronotherapeutic drug delivery systems that release a 
therapeutic agent at a rhythm to maintain the adequate 
drug concentration according to the needs of the 
physiological states of patient’s body and the circadian 
rhythm. The goal is to distribute the drug in high 
concentration in accordance with need of time and in 
less concentration when the requirement is little to 
reduce side effects. 
Concept of circadian rhythm 
A Circadian Rhythm is any biological process that 
displays an endogenous, entrainable oscillation of 
about 24 h. Biological systems possesses a very 
prominent temporal structure.  
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It was believed that cyclic changes in organisms 
represented exclusively the simultaneous effects of 
cyclic changes in environmental factors, such as the 
alternation of light with darkness and/or of heat with 
cold over periods of both 24 h and 1 year. Major 
periodic components of biological rhythms are found 
around 24 hr and 1year [2]. Circadian rhythms are 
controlled by an inherited master clock network 
composed of the paired suprachiasmatic nuclei (SCN) 
that are situated in the hypothalamus and the pineal 
gland. The rhythmic activities of specific, so-called, 
clock genes like per1, per2, per3, bmal, clock, and 
CRY, among others, and their gene products, plus the 
cyclic (nocturnal) secretion of melatonin from the 
pineal gland comprise the central timekeeping 
mechanism. This master clock network orchestrates the 
period and phase of the multitude of subservient 
peripheral circadian clocks located in cells, tissues, and 
organ-systems. The end-effect is a rather exquisite 
temporal organization of biological processes and 
functions. Biological timekeeping is an evolutional 
adaptation to an environment that is organized in time, 
displaying discrete and important cyclic phenomenon. 
Thus, the temporal organization of biological processes 
and functions during the 24-h period ensures peak 
functioning of the diurnal human species during 
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daytime activity and restoration and repair during 
nocturnal rest [3]. 
Thus it is found that Circadian rhythm regulates many 
body functions in humans, viz., metabolism, 
physiology, behavior, sleep patterns, hormone 
production, etc.  
Rheumatoid arthritis 
RA is a chronic disorder in which, the body's own 
immune system starts to attack body tissues, reasons of 
which are unknown. This disorder is accompanied with 
swelling, stiffness and pain In this disorder the attack is 
not only directed at the joint but to many other parts of 
the body. In RA, the joint lining and cartilage gets 
more damaged which eventually results in erosion of 
two opposing bones. Body parts which get affected in 
RA are joints in the fingers, knees, wrists, and elbows. 
Advanced disease stages can lead to substantial loss of 
functioning and mobility.  The triggers for the onset of 
RA are only speculated, but it is expected that a genetic 
liability to the disorder, several viruses and bacteria 
(e.g. EpsteinBarr-Virus and Mycobacterium 
tuberculosis; disruption of the immunological tolerance 
as well as the psychological condition by further 
weakening the immune system of people concerned 
could play a major role . As the causes for RA are still 
unknown, cures have not been discovered yet as well 
[4]. All treatments and therapies which are applied so 
far are intended largely to reduce symptoms and delay 
the progress of the disease. The onset of RA occurs 
usually between the age of 30 and 50, but may also 
occur at any other age. Women are three times more 
affected by it than men and people who are less 
educated and with fewer socioeconomic resources 
experience more problems emerging of RA. In 
children, the disorder can present with a skin rash, 
fever, pain, disability, and limitations in daily 
activities. About 1% of the whole world population is 
attacked by RA [5]. No one knows why RA occurs and 
all treatments are focused on easing the symptoms. 
Pain and fatigue is mainly associated with this disorder 
and with earlier diagnosis and aggressive treatment, 
many individuals can lead a decent quality of life.  
Rheumatologists have experienced it clinically that 
patients with RA experience joint pain, morning 
stiffness, and functional disability in the early morning 
hours. These diurnal variations display large 
amplitudes, with the patient’s condition being poor in 
the early morning and disease activity being mild or 
moderate in the early evening (Figure 1). This was 
presented by using grip strength as a parameter; grip 
strength (a nonspecific index, influenced by muscle 
power and pain) was, on average, 233 mm Hg at 6:00 
AM and 297 mm Hg at 6:00 PM, an increase of 
27.5% [6], further exemplified by overall pain reported 
using a 0–10-point visual analog scale, with an average 
pain score of 6.3 at 8:00 AM and 4.5 at 6:00 PM 
(decrease of 28.6%) [7].   
 
Fig 1: Clinical signs and symptoms of articular inflammation in patients with RA change consistently as a 
function of the hs of the day: pain and joint stiffness are greater after waking up in the morning than in the 
afternoon or evening [8] 
Therefore it was concluded that clinical signs and 
symptoms in RA show a rhythm that seems driven by a 
biological clock and it was observed that daily 
oscillations in circulating concentrations of disease-
mediating cytokines are responsible for such kind of 
diurnal variations. Two hormones which act as 
circadian agent are glucocorticoids and melatonin. 
Both are important in inflammation and regulation of 
the immune response, and may contribute to the 
pathogenesis of RA. In Figure 2 it is depicted that joint 
stiffness and pain are more pronounced in the early 
morning, and this correlates with the early morning rise 
in plasma IL-6 levels. The circadian hormone 
melatonin (which is considered to exacerbate the 
inflammatory response) is released only during the 
night, and circulating levels peak in the mid-night. The 
anti-inflammatory glucocorticoid - cortisol - is also 
under circadian control, peaking in the early 
morning. In adult primates,retina receives  only visible 
light (400–700 nm). This photic energy is transduced 
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and delivered to visual cortex and then to the 
suprachiasmatic nucleus, the hypothalamic region that 
directs circadian rhythms. Exposure to visible light 
modulates the pituitary and pineal glands, leading to 
neuroendocrine changes. Levels of Norepinephrine, 
melatonin and acetylcholine decrease with light 
activation, whereas cortisol, serotonin, γ-aminobutyric 
acid, and dopamine levels increase[9].  
 
 
 
Figure 2: RA shows diurnal variation in disease symptoms and markers[10] 
 
Circadian Rhythm of hormones  
 Glucocorticoid Tumor necrosis factor 
(TNF)/interleukin-6 (IL-6) are the inflammatory 
cytokines which are soluble products of the activated 
immune system and these stimulate the production of 
corticotropin- releasing hormone (CRH) in the 
hypothalamus. This leads to the production of 
corticotropin, followed by glucocorticoid secretion by 
the adrenal cortex [11-12]. All these components 
constitute the hypothalamic – pituitary–adrenocortical 
(HPA) axis. Increased functioning of HPA axis 
function resulting in increased cortisol production is a 
normal response to the stress of inflammation. Cortisol 
production is associated with the increased production 
of the Th2 cytokines (e.g.: IL- 10) ,observed in the 
early morning, following the Th1 cytokine 
peaking.[13] It was revealed from the studies that in 
case of patients suffering from RA overall activity of 
the HPA axis remained inappropriately normal which 
was found insufficient to inhibit ongoing inflammation 
[14]. Also, it is reported that there exist a negative 
correlation betweenof cortisol and IL-6 indicating that, 
in RA HPA function is insufficient to inhibit ongoing 
inflammation. In other studies decreased plasma levels 
of the adrenal androgen (AAs) dehydroepiandrosterone 
(DHEA) and its sulfate metabolite were found [15]. 
After correlating all these levels early morning IL-6 
peak values were found greater in RA patients than in 
their healthy controls. [15-16]   
Melatonin Level of melatonin increases progressively 
from 8 pm to the early morning hours inboth patients 
with RA as well as healthy subjects; however,in case of 
RA melatonin  reaches at  peak level at midnight 
which is at least 2 h earlier compared to controls. It 
was reported that melatonin concentrations in patients 
who had RA reached a plateau that lasted for 2 to 3 h; 
this was not observed in controls. After 2 am, level of 
melatonin decreases in both patients who had RA and 
healthy subjects. Thus it was confirmed that nocturnal 
rhythm of melatonin occurs also in patients who have 
RA, but with an earlier peak level and a longer duration 
in the early morning [17]. IFN-g, IL-1, IL-2, IL-6, IL-
12, and TNF-a production (Th1 cytokines) reaches 
peak during the night and early morning, at the same 
time that MLT serum levels are highest and plasma 
cortisol is lowest.  It was found thatmelatonin 
was present in high concentration in synovial fluids in 
patients who had RA and binding sites for MLT were 
present in synovial macrophages resulting in increased 
proinflammatory cytokine production [18-19]. 
Similarly, Chikanza et al., 1993 [20] found that serum 
levels of prolactin during the night were significantly 
higher in RA patients compared with controls, and this 
has been confirmed by others [21]. 
Chronotherapy for RA  
As discussed above RA symptoms follow a 
circadianpattern, therapy based on these rhythms 
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(chronotherapy) has not yet been developed. In this 
section chronotherapies that have been observed in 
basic and clinical studies based on this is 
discussed.Approach used to treat patients with RA 
depends upon the timely and judicious use of several 
types of therapeutic interventions which include early 
diagnosis, care by an expert in the treatment of 
rheumatic diseases (rheumatologist) early use of 
DMARDs with the target of remission or low disease 
activity and use of anti-inflammatory agents, including 
non-steroidal anti-inflammatory drugs (NSAIDs) and 
glucocorticoids. There are various studies that are 
based on development of chronotherapeutic system that 
synchronize with the diseased condition.  
Glucocorticoids have been used in RA therapy as it 
posses the anti inflammatory activity against the joint 
pain and joint stiffness. As discussed earlier Cortisol is 
an endogenous glucocorticoid, which reaches the peak 
in the morning in humans. In order to prevent 
disturbances in the circadian rhythms of endogenous 
glucocorticoids steroids are generally administered in 
the morning. Studies were conducted by Silva et al., 
1984 [22] and Arvidson et al., 1994 [16] to observe the 
dependency on dosing time of drug administered in the 
morning or night according to the 24-h rhythms of 
endogenous glucocorticoids and RA symptoms. The 
findings revealed that the duration of morning stiffness 
and blood IL-6 levels were markedly shorter and lower, 
respectively, in the night dosing group than in the 
morning dosing group. 
In recent years, chronotherapeutic delivery systems of 
glucocorticoids have improved the outcomes. 
Buttgereit et al., 2008 [23] performed a multicentre, 
randomized, double-blind trial, in which a modified-
release formulation of prednisone was developed, 
which releases the agent -4 h after its ingestion. 
Patients with RA were randomly given a modified-
release tablet at bed-time or an immediate-release 
prednisone tablet in the morning; relative changes in 
the duration of joint morning stiffness were 
significantly higher with the modified-release tablet 
than with the immediate-release tablet. It was also 
reported thatchronotherapy with nighttimerelease may 
improve the efficacy of long-term low-dose 
glucocorticoid treatment [24-26].Disease-modifying 
antirheumatic drugs (DMARDs) are 
commonly characterized by their capacity to reduce 
or reverse signs and symptoms, disability, 
impairment of quality of life, and progression of joint 
damage and thus to interfere with the entire disease 
process[27]DMARDs form two major 
classes: synthetic chemical compounds (sDMARDs) 
and biological agents (bDMARDs). Methotrexate is 
one of the most commonly used disease-modifying 
antirheumatic drug. On the basis of clinical trial it was 
revealed that administering Methotrexate at specific 
times in accordance with the 24-h rhythm of TNF-α 
leads to decreased inflammatory responses to RA. 
Based on animal study and 24-h rhythm of TNF-α in 
RA patients it was observed that Methotrexate given 
once-a-day at bedtime improved the disease activity 
and patient’s functional capacity[28-29]. 
Conclusion 
RA exhibit diurnal rhythmicity. Joint pain, stiffness 
and functional disability is at its most severe in early 
morning. The treatment of such symptoms can be 
improved by the administration of the dose at the 
nighttime, by which thein vivo drug availability 
coordinates with the rhythms of disease, and thus 
therapeutic outcomes can be optimized.   
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